Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 4, April, p. 455–461

doi: 10.17219/acem/70800

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Levels of EGF and VEGF in patients with primary and secondary Sjögren’s syndrome

Katarzyna J. Błochowiak1,A,B,C,D,E,F, Dorota Trzybulska2,B,C,E,F, Anna Olewicz-Gawlik2,A,B,E,F, Jan J. Sikora3,E,F, Michalina Nowak-Gabryel4,B,E,F, Jarosław Kocięcki4,E,F, Henryk Witmanowski5,E,F, Jerzy Sokalski6,A,E,F

1 Department of Dental Surgery, Poznan University of Medical Sciences, Poland

2 Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poland

3 Department of Immunology, Poznan University of Medical Sciences, Poland

4 Department of Ophthalmology, Poznan University of Medical Sciences, Poland

5 Department of Plastic, Reconstructive and Aesthetic Surgery, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland

6 Department of Oral Surgery, Poznan University of Medical Sciences, Poland


Background. Aberrant angiogenesis plays a role in the pathogenesis of Sjögren’s syndrome (SS).
Objectives. The aim of this study was to compare the levels of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) in stimulatory parotid saliva and in serum in healthy subjects (HS), patients with primary SS (pSS) and secondary SS (sSS) and to evaluate the expression of EGF, proangiogenic VEGF165 and antiangiogenic VEGF165 b mRNA isoforms. Additionally, we determined the salivary levels of serine/arginine splicing factor (SRSF1), which regulates VEGF165 and VEGF165 b expression.
Material and Methods. The study comprised 34 women (16 with pSS and 18 with sSS) and healthy subjects for blood and saliva sampling. EGF and VEGF levels in saliva and serum and salivary SRSF1 levels were determined by enzyme-linked immunosorbent assay (ELISA). The expression of VEGF165 , VEGF165 b and EGF in peripheral blood mononuclear cells (PBMC) was evaluated by quantitative polymerase chain reaction (qPCR).
Results. There were no differences in the levels of EGF, VEGF, SRSF1 and in the expression of the EGF, VEGF165 and VEGF165 b between HS and SS patients, or between pSS and sSS patients. The salivary levels of VEGF165 and EGF were significantly higher in pSS, sSS and HS than serum levels. Levels of SRSF1 correlated positively with VEGF and EGF levels. Levels of EGF, VEGF and SRSF1 correlated with each other.
Conclusion. The balance of VEGF isoforms is not disturbed in SS. Saliva is more sensitive for the detection of EGF and VEGF than serum, but salivary levels of those proteins are not representative for SS.

Key words

Sjögren’s syndrome, angiogenesis, vascular endothelial growth factor, epidermal growth factor

References (37)

  1. Fox RI. Sjögren’s syndrome. Lancet. 2005;366:321–331.
  2. Fox RI, Liu AY. Sjögren’s syndrome in dermatology. Clin Dermatol. 2006;24:393–413.
  3. Lisi S, Sisto M, D’Amore M, Lofrumento DD. Emerging avenues linking inflammation, angiogenesis and Sjögren syndrome. Cytokine. 2013;61:693–703.
  4. Tayama M, Furuhata T, Inafuku Y, et al. Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World J Gastroenterol. 2011;17:4867–4874.
  5. Manetti M, Guiducci S, Romano E, et al. Increased plasma levels of the VEGF165b splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. Ann Rheum Dis. 2013;72:1425–1427.
  6. Manetti M, Guiducci S, Romano E, et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res. 2011;109:14–26.
  7. Dokun AO, Annex BH. The VEGF165b “ICE-o-form” puts a chill on the VEGF story. Circ Res. 2011;109:246–247.
  8. Qiu Y, Ferguson J, Oltean S, et al. Overexpression of VEGF165b in podocytes reduces glomerular permeability. J Am Soc Nephrol. 2010;21:1498–1509.
  9. Nowak DG, Woolard J, Amin EM, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci. 2008;121:3487–3495.
  10. Rennel ES, Waine E, Guan H, et al. The endogenous anti-angiogenic VEGF isoform, VEGF 165b inhibits human tumour growth in mice. Br J Cancer. 2008;98:1250–1257.
  11. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, et al. Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. Eur J Cancer. 2008;44:1883–1894.
  12. Hua J, Spee Ch, Kase S, et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51:4282–4288.
  13. Fox PC, Speight PM. Current concepts of autoimmune exocrinopathy: Immunologic mechanism in the salivary pathology of Sjögren’s syndrome. Crit Rev Oral Biol Med. 1996;7:144–158.
  14. Vitali C, Bombardieri S, Jonsson R. Classification criteria for Sjögren syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.
  15. Westergren A. Diagnostic tests: The erythrocyte sedimentation rate range and limitations of the technique. Triangle. 1957;3:20–25.
  16. Najafi L, Malek M, Valojerdi AE, Khamsch ME, Abhaei H. Dry eye disease in type 2 diabetes mellitus; comparison of the tear osmolarity test with other common diagnostic test: A diagnostic accuracy study using STARD standard. J Diab Met Dis. 2015;14. doi:10.1186/s40200-015-0157-y
  17. Chen A, Chin HT, Hwang YH, Hsiao CH, Chen HC. Severity of dry eye syndrome in related to anti-dsDNA autoantibody in systemic lupus erythrematosus patients without secondary Sjogren sydrome. Medicine. 2016;95:4218.
  18. Trzybulska D, Olewicz-Gawlik A, Graniczna K, et al. Quantitative analysis of elastase and cathepsin G mRNA levels in peripheral blood CD14(+) cells from patients with rheumatoid arthritis. Cell Immunol. 2014;292:40–44.
  19. Miller-Kasprzak E, Jagodziński PP. 5-Aza-2’-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells. Biomed Pharmacother. 2008;62:158–163.
  20. Beştaş R, Kaplan MA, Işikdoğan A. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma. Hepatogastroenterology. 2014;61:267–271.
  21. Ferreira Duque JL, Loughlin KR, Adam RM, Kantoff P, Mazzucchi E, Freeman MR. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: Relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. doi:org/10.1590/S1807-59322006000500006
  22. Skopiński P, Skopińska-Różewska E, Jung L, Sommer E, Chorostowska-Wynimko J, Wasiutyński A. Age-dependence of angiogenic activity of human serum. Centr Eur J Immunol. 2009;34:53–56.
  23. Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol. 2007;27:246–256.
  24. Sisto M, Lisi S, Lofrumento DD, D’Amore M, Ribatti D. Neuropilin-1 is upregulated in Sjögren’s syndrome and contributes to pathological neovascularization. Histochem Cell Biol. 2012;137:669–677.
  25. Robak E, Sysa-Jędrzejewska A, Robak T. Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Med Inflamm. 2003;12;293–298.
  26. Sisto M, Lisi S, Ingravallo G, Lofrumento DD, D’Amore M, Ribatti D. Neovascularization is prominent in the chronic inflammatory lesions of Sjögren’s syndrome. Int J Exp Path. 2014;95;131–137.
  27. Sisto M, Lisi S, Lofrumento DD, D’Amore M, Frassanito MA, Ribatti D. Sjögren’s syndrome pathological neovascularization is regulated by VEGF-A-stimulated TACE-dependent crosstalk between VEGFR2 and NF-κB. Genes Immun. 2012;13:411–420.
  28. Hernández-Molina G, Ávila-Casado C, Cárdenas-Velázquez F, et al. Similarities and differences between primary and secondary Sjögren’s syndrome. J Reumathol. 2010;37:800–808.
  29. Salliot C, Mouthon L, Ardizzone M, et al. Sjögren’s syndrome is associated with and not secondary to systemic sclerosis. Rheumatology. 2007;46:321–326.
  30. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren’s syndrome: Why autoimmune epithelitis? Oral Diseases. 2006;12:523–532.
  31. Wollard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–7835.
  32. Díaz R, Peña C, Silva J, et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer. 2008;123:1060–1067.
  33. Hernández-Molina G, Michel-Peregrina M, Hernández-Ramírez DF, Sánchez-Guerrero J, Llorente L. Chemokine saliva levels in patients with primary Sjögren’s syndrome, associated Sjögren’s syndrome, pre-clinical Sjögren’s syndrome and systemic autoimmune diseases. Rheumatology. 2011;50:1288–1292.
  34. Moriyama M, Hayashida JN, Toyoshima T, et al. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren’s syndrome. Clin Exp Immunol. 2012;169:17–26.
  35. Bertorello R, Cordone MP, Contini P, et al. Increased levels of interleukin-10 in saliva of Sjögren’s syndrome patients. Correlation with disease activity. Clin Exp Med. 2004;4:148–151.
  36. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren’s syndrome. Oral Dis. 2009;15:519–526.
  37. Nagashima M, Wauke K, Hirano D, et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology. 2000;39:1255–1262.